



RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

October 29, 2026

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Investor Presentation - Financial Results

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH
RAMESH SHIRAMBEKAR
Date: 2026.10.29 23:11:57
+05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl: as above

FY27: Q2 & H1 Performance

RPG Life Sciences

Investors' Presentation

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Group: Powered by Passion, Driven by Ethics

UNLEASHTALENT
TOUCHLIVES
OUTPERFORM
AND😊

RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India's fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn



EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables



One of India's leading tyre manufacturers



Global technology consulting and IT services company



Integrated pharma company in formulations and synthetic APIs



Technology solutions company catering to energy and infrastructure



One of India's largest plantation companies producing tea, rubber, etc.



RPGLS Company Overview

RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated pharmaceutical company operating in the Domestic and International markets in the Branded Formulations, Global Generics, and Synthetic APIs

OUR VALUES



**Quality
Consciousness**



**Operational
Excellence**



**Responsible
Growth**



**Strong ESG
&
Governance**



50+ years
of Rich Legacy



63+ countries
with export relationships



6 textbook brands
trusted by patients and doctors




**5 Manufacturing
Facilities**
Formulations, API & Intermediates



1,800+
Employees across locations

REVENUE MIX BY CATEGORIES



Domestic Formulations
International Formulations
API

Board of Directors




Mr. Harsh V. Goenka
Chairman



Mr. Ashok Nair
Managing Director



Ms. Vasundhara Patni
Non-Executive Director



Mr. Manoj K. Maheshwari
Non-Executive Director



Mr. Hiten Kotak
Independent Director



Mr. Bhaskar Iyer
Independent Director



Mr. Anil Matai
Independent Director



Ms. Radhika Gupta
Independent Director



Ms. Zahabiya Khorakiwala
Independent Director



Dr. Pratit Samdani
Independent Director



Mr. Sachin Nandgaonkar
Independent Director



Mr. Rajat Bhargava
Non-Executive Director



Mr. Yugal Sikri
Non-Executive Director

- Experienced professionals and industry veterans from various sectors, including pharmaceuticals, business management, and corporate governance.

- The board has specialized committees, such as the Audit Committee, Corporate Social Responsibility (CSR) Committee, and the Nomination and Remuneration Committee, ensuring focused management of critical areas.

RPG Life Sciences: Product Portfolio, Textbook brands; focus on chronic & specialty therapies

Key Therapies

Nephrology

Rheumatology

Oncology

Pain Management

Gastroenterology

Neuropsychiatry

Cardio- Diabeto

Urology

DF Key Products

Legacy Portfolio

Immunosuppressants	Azoran [®] Azathioprine	Mofetyl [®] Mycophenolate Mofetil	ArpimuneME [®] Cyclosporine	Imunotac [®] Tacrolimus		
Textbook Brands	Azoran [®] Azathioprine	Aldactone [®] Spironolactone	Lomotil [®] Diphenoxylate HCl	 Naprosyn [®] Naproxen	Serenace [®] Haloperidol	Norpace ^{New} Disopyramide Phosphate

New Portfolio

Specialty	HerMab [®] Trastuzumab	Adiumab [®] Adalimumab	Ivzumab [®] Bevacizumab	Zestmab [®] Rituximab	T-JAKI [®] Tofacitinib	FC-IRO [®] Ferric Carboxymaltose	Denbri [®] Denosumab	
Chronic	Azoran [®] 75 Azathioprine 75 mg	Aldactone ^T 25/50 Spironolactone 25/50 mg	Aldactone ^F Spironolactone 50 mg + Furosemide 20 mg	Naprosyn [®] + Naproxen Sodium + Esomeprazole	Naprosyn [®] Gel THE PAIN RELIEF EXPERT	Naprosyn ^M Sustained Naproxen 500 mg	ROMILAST-BL Bromelain + Trypsin	TricaineAlma ² Piroxicam + Thiocolchicoside 2 mg
Life cycle Management	SacuNew [®] Sacubitril+ Valsartan	NuGliptin [®] Vildagliptin	GliptiNext [®] Teneligliptin	DPO [®] 10/5 Dapagliflozin	Solifirst [™] Solifenacin	Mirasmart [®] S Mirabegron + Solifenacin		


IF Key Products

Generics	Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline
Branded Generics	Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope

API & Intermediates Products

API	Quinifamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole
Intermediates	Rivaroxaban Intermediates, Apixaban Intermediates, Dofetilide Intermediates, Deferasirox Intermediate

50+ years of RPGLS journey- A snapshot



External Awards & recognition

Recognised for excellence in innovation, commercial performance and responsible business practices




Leading Nephrology Company-2026



Excellence in Breakthrough Pharmaceutical Innovations



Best Use of AI in Sales Force Effectiveness



Leading Mid Corporates of India- 2025



India's Top 500 Value Creators -2023



Best Patent Award



Fair Business Practices Award



Best Corporate Citizen Award



Our Business Segments

Domestic Formulations : Overview and Strategy

Business Overview



Pan-India presence

Reach to over 1 lakh doctors and 3000+ stockiest



Diverse portfolio

Across chronic, sub-chronic and acute segment



Established brands

Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace



Strong therapy presence

Cardiology, diabetes, urology, nephrology, rheumatology and oncology

Five pillars of profitable domestic growth



Portfolio Rejuvenation

Strengthen chronic and specialty portfolios through new product launches.



Strategic Brand Building

Extend brand lifecycles through line extensions and deeper disease-segment penetration.



Customer Coverage Deepening

Expand customer reach and deploy digital engagement across priority therapies.



Sales Force Effectiveness

Improve field-force productivity through sharper targeting, stronger capabilities and execution.



Cost discipline

Strengthen margins through cost discipline, operating efficiency and a focus on profitable sales mix.

Domestic Formulations: Key performance highlights



4th fastest

**Growing company
among Top 50 in IPM¹**

DF H1 growth at 13.0%; 1.2
times faster than market



12 ranks

**Jump in market
rank since Mar'25**

Up from Rank 62 in Mar'25 to
Rank 50 in Sep'26



₹100 cr

**Naprosyn crosses
the milestone in
secondary sales**

Flagship brand, 50+ years of
trust

1. IPM: Indian Pharma Market

Manufacturing facilities for domestic and international formulations

F1 Unit



- Serves **domestic** and **20+ emerging markets**, ensuring global accessibility
- State-of-the-art **multipurpose plant** with **dedicated lines** for oral dosage forms – tablets, liquids, and powders
- Installed capacity of **177 crore tablets** and **88.5 lakh bottles** annually, supporting large scale demand
- Approved by **WHO, Kenya, and Nigeria** regulatory authorities
- **Modernization** and **capacity expansion** in progress to boost efficiency and scalability

F2 Unit



- Dedicated to **highly regulated markets**, ensuring compliance and quality excellence
- Advanced lines for **oral dosage forms** – tablets and capsules – with stringent controls
- Equipped for **low RH** and **low temperature products**, meeting complex formulation needs
- Annual output of **12 crore tablets** and **3.6 crore capsules**, supporting global demand
- Approved by **WHO, EUGMP (Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan, Nigeria**
- Ongoing **modernization and capacity expansion** to enhance scale and efficiency

State-of-the-art Manufacturing Facility



API & Intermediates Business : Overview and Strategy

Business Overview



50+ Markets served

US, Europe, LATAM, Asia Pacific & MENA regions



490 KL capacity

Combined API & Intermediates capacity



3 Manufacturing units

Located in Navi Mumbai, Hyderabad & Vizag



Strong Approvals

WHO GMP, TGA Australia, PMDA Japan

Three pillars to scale the API business



Market and customer expansion

- Grow reach for existing products in new and established markets



Integration & Synergy Realisation

- Integrate acquired capabilities, strengthen operational alignment and unlock synergies across the API platform



Forward Integration & value creation

- Strengthen the value chain through downstream opportunities, portfolio expansion and higher-value offerings.

API business transitions into a dedicated subsidiary called RPGAP

Strategic investments and acquisitions are expanding the API platform's capabilities and manufacturing footprint

1. Formed a dedicated API subsidiary



- **RPG Active Pharma** established as a dedicated subsidiary for the API business

2. Strategic capital commitment



- **Strategic PE, InvAscent onboarded;** ₹700 crore of combined committed capital pool created

3. Advanced Intermediates Expansion



- **Acquisition of Actis**, adding advanced intermediates capabilities

4. Manufacturing Scale-Up



- **Acquisition of Raghava Life Sciences**, adding a modern API and intermediates manufacturing facility

API & Intermediates manufacturing facility

Navi Mumbai Plant



- Three specialized units
 - MF1: multipurpose unit serving **emerging markets**, including India.
 - MF2: **dedicated immunosuppressant facility** for regulated and emerging markets.
 - **MF3**: multipurpose unit for **regulated** and **emerging markets**
- Installed capacity: **60.4 MT annually and 36 reactors**
- Global accreditations: **WHO, TGA (Australia), PMDA (Japan), and Written Confirmation (WC)** from **CDSO**.

Hyderabad Plant



- **API & intermediate manufacturing facility** with established regulatory approvals
- **Current capacity: 188.2 MT annually | 49 reactors**
- **4 dedicated manufacturing blocks**
- **Kilo Lab: 1.5 KL capacity | 4 reactors**
- **Regulatory approvals: WHO GMP, EU GMP and CDSCO**
- **ISO 9001, ISO 14001 & ISO 45001 certified**

Vizag Plant



- Four specialized manufacturing blocks developing advanced intermediates for many APIs **including Sitagliptin, Rivaroxaban and Vildagliptin**
- Installed capacity: **142.9 MT annually and 43 reactors**

International Formulations : Overview and Strategy

Business Overview



50+ Markets served

Across Europe, UK, Canada, Australia, Southeast Asia, Latin America, Africa & other emerging markets



5 Therapy presence

Immunosuppressant, Cardio, Neuro, Gastro & Uro



2 Manufacturing units

Located in Ankleshwar, Gujarat



Strong Regulatory Track

TGA Australia, EU GMP, Health Canada, Zazibona, UAE MOH, Saudi FDA

Three pillars to scale the IF business



Build and expand core portfolio

- Grow presence in immunosuppressants and other focus therapies
- Leverage existing products in new markets



Strengthen pipeline and partnerships

- Focus on complex generics and high-value opportunities
- Collaborate with global players to expand portfolio



Scale presence in priority markets

- Deepen relationships with existing customers
- Build on manufacturing and regulatory strengths to support global growth




Financial Performance


Q2 FY27 Financial Performance Update: Revenue up by 16.2% with improved profitability

(All figures in Rs. Crores)
Figures in circle are Margins


Revenue from Operations




Adjusted EBITDA & EBITDA Margin



Adjusted PBT & PBT Margin



Adjusted PAT & PAT Margin




Adjusted margins excludes one-off restructuring and API acquisition costs of ₹5.5 crore, incurred in Q2 FY27


Q2 FY27: Business segment wise performance

(All figures in Rs. Crores)


Domestic Formulations (69% of sale)



International Formulations (18% of sale)



API¹ (13% of sale)




1. API Q2 FY27 sales include 0.5 cr. of sale from newly acquired business, Actis Generics


H1 FY27 v/s H1 FY26: Financial Performance Update

(All figures in Rs. Crores)
Figures in circle are Margins


Revenue from Operations




Adjusted EBITDA & EBITDA Margin



Adjusted PBT & PBT Margin



Adjusted PAT & PAT Margin




Adjusted margins excludes one-off restructuring and API acquisition costs of ₹5.5 crore, incurred in Q2 FY27


H1 FY27: Business segment wise performance

(All figures in Rs. Crores)


Domestic Formulations (69% of sale)



International Formulations (17% of sale)



API¹ (14% of sale)




1. API H1 FY27 sales include 0.5 cr. of sale from newly acquired business, Actis generics

RPG Life Sciences' Market Capitalisation Rises 64% in H1 FY27

Significantly outperforming the Sensex and BSE Healthcare Index

RPGLS market cap, ₹ cr



- All-time high market-cap of RPGLS unlocked on 25th Sept 2026

Market-outperformance

BSE Sensex growth at only 1%, BSE Healthcare Index growth at 20% in the same period

Trading at a P/E ratio of 40+

Much-higher compared to peer benchmarks (peer average around 23-25)



Other key highlights

Digital Initiatives: Manufacturing and Quality



Digital Retina Scanner

- Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures
- Access to only qualified professionals, Batch Management, Recipe Management, Audit logs

Intelligent Chilling Plant Manager

- Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics

IOT based AHU monitoring system

- Operates Pumps & Chillers according to Operating Hours to maintain equal run time
- Automatically change over Working pump to Standby if Pump fails during operation

Power Management System

- Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets always enabled

Quality Functions

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

AI Initiatives: Embedding intelligence across the business

AI-Enabled Customer Engagement



- RPGserv is an AI-enabled digital doctor-support platform enhancing physician engagement through scientific content, patient education and personalised services

Smarter Commercial Decision-Making



- GenAI-powered campaign dashboards and data analysis
- RXR 3.0: Salesforce tracking and customer engagement analytics to support data-led decisions

AI-Powered Marketing & Communication



- AI-assisted brand communication, content creation and training modules
- Development of customised digital creatives for targeted engagement

Building AI-Ready Leadership



- Launched Slingshot, an advanced AI training programme for the leadership team to drive AI adoption and identify high-impact use cases across business functions

Happiness initiatives: Engaging teams beyond work

Building connection, celebrating traditions and creating shared experiences

Independence Day Celebrations

Moments of national pride & unity



Festival Celebrations

Celebrating our diverse traditions



Employee Engagement

Strengthening teamwork through fun experiences





Journey Ahead

RPGLS Journey Ahead: 7 strategic pillars of action

Portfolio
development and
mega-brands
building

Expand market
reach, customer
relationships and
capabilities

Drive productivity,
efficiency and
compliance through
digitalisation

Integrate, Scale &
Grow the API
Business

Build the pipeline
and expand into
adjacent
therapies

Strengthen
capacity, quality
and operational
efficiency

Build critical
capabilities and
strengthen
organisational
effectiveness

1

2

3

4

5

6

7



RPGLS LIFE SCIENCES



THANK YOU

